Antilipidemic Drugs

Correct Answer

C — Icosapentaenoic acid ethyl ester

Rationale

Icosapentaenoic acid ethyl ester is the prescription omega-3 fatty acid formulation with proven cardiovascular outcomes evidence. The REDUCE-IT trial demonstrated a 25 percent reduction in major cardiovascular events when icosapentaenoic acid ethyl ester 4 grams per day was added to statin therapy in patients with elevated triglycerides and established atherosclerotic cardiovascular disease or diabetes with additional risk factors. Over-the-counter fish oil products contain docosahexaenoic acid and have not demonstrated cardiovascular event reduction in adequately powered trials. A large trial of high-dose icosapentaenoic acid plus docosahexaenoic acid found no reduction in cardiovascular events, and a primary prevention trial of lower-dose icosapentaenoic acid plus docosahexaenoic acid also found no significant benefit.

Correct Answer

A — Colesevelam

Rationale

Colesevelam is the bile acid sequestrant classified as having an additional approved indication for modest reduction of glycated hemoglobin — approximately 0.5 percent — in type 2 diabetes, making it potentially useful in patients with combined hypercholesterolemia and diabetes who need low-density lipoprotein cholesterol lowering without systemic drug exposure. Cholestyramine and colestipol are older bile acid sequestrants that share the same primary lipid-lowering mechanism but do not have this additional diabetes indication. Fenofibrate is a fibrate, not a bile acid sequestrant, and its primary indication is triglyceride reduction.

Correct Answer

D — Pemafibrate

Rationale

Pemafibrate is classified as a selective peroxisome proliferator-activated receptor-alpha modulator. Unlike conventional fibrates, which are full peroxisome proliferator-activated receptor-alpha agonists, pemafibrate selectively activates specific aspects of peroxisome proliferator-activated receptor-alpha signaling. Despite robust triglyceride lowering, pemafibrate failed to reduce cardiovascular events in a large clinical trial, reinforcing the conclusion that triglyceride lowering per se does not translate into cardiovascular benefit in patients already on statin therapy. Fenofibrate and gemfibrozil are classified as conventional peroxisome proliferator-activated receptor-alpha agonists, not selective modulators. Niacin acts through the GPR109A receptor on adipocytes, an entirely different target.

Correct Answer

B — Fenofibrate

Rationale

Fenofibrate is classified as requiring renal dose adjustment because it undergoes renal excretion. In patients with significant kidney disease, fenofibrate accumulates and the dose must be reduced or the drug avoided entirely to prevent toxicity, including the risk of myopathy. This is an important practical consideration when selecting a fibrate for a patient with chronic kidney disease who has severe hypertriglyceridemia requiring pharmacological treatment. Gemfibrozil is eliminated primarily by glucuronidation and does not require renal dose adjustment to the same degree, but it carries a substantially higher risk of myopathy when combined with statins due to its inhibition of hepatic uptake transporters. Clofibrate is an older fibrate with limited current use.

Correct Answer

C — Cholestyramine and colestipol

Rationale

Cholestyramine and colestipol are both classified as granular powder formulations — older bile acid sequestrant preparations that must be mixed with liquid before ingestion. Their gritty texture and gastrointestinal adverse effects including constipation, bloating, flatulence, and nausea contribute to poor tolerability and limit patient adherence. Colesevelam is a newer bile acid sequestrant available as a tablet, which improves tolerability substantially and also has an additional approved indication for modest glycated hemoglobin reduction in type 2 diabetes. All three agents share the same primary mechanism of binding bile acids in the intestinal lumen, but differ in formulation and in their additional indications.

Correct Answer

A — Fibrates

Rationale

Fibrates — including fenofibrate and gemfibrozil — are classified as peroxisome proliferator-activated receptor-alpha agonists. Peroxisome proliferator-activated receptor-alpha is a nuclear receptor found predominantly in the liver, skeletal muscle, and heart; its activation by fibrates produces a coordinated transcriptional program that reduces triglyceride synthesis and increases triglyceride catabolism. Bile acid sequestrants act by binding bile acids in the intestinal lumen and are not receptor agonists. Statins are classified as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Proprotein convertase subtilisin/kexin type 9 inhibitors are classified as either monoclonal antibodies or small interfering ribonucleic acid agents targeting the proprotein convertase subtilisin/kexin type 9 pathway.

Correct Answer

B — Fibrates activate peroxisome proliferator-activated receptor-alpha, upregulating lipoprotein lipase and apolipoprotein A-I and A-II while downregulating apolipoprotein C-III, increasing triglyceride-rich particle clearance and high-density lipoprotein synthesis

Rationale

Fibrates activate peroxisome proliferator-activated receptor-alpha, a nuclear receptor that drives a coordinated transcriptional program with multiple simultaneous effects. Upregulation of lipoprotein lipase increases hydrolysis of triglyceride-rich very low-density lipoprotein and chylomicron particles. Downregulation of apolipoprotein C-III — a natural inhibitor of lipoprotein lipase — further amplifies triglyceride clearance. Upregulation of apolipoprotein A-I and apolipoprotein A-II increases high-density lipoprotein cholesterol synthesis. The net result is triglyceride reduction of 20 to 50 percent and high-density lipoprotein cholesterol increase of 10 to 20 percent. Option A describes the statin mechanism. Option C describes the bile acid sequestrant mechanism. Option D describes the niacin mechanism via the GPR109A receptor.

Correct Answer

D — Triglyceride lowering alone, in the modern statin era, does not translate to cardiovascular benefit — the current role of fibrates is therefore limited to severe hypertriglyceridemia above 500 milligrams per deciliter, where the immediate goal is pancreatitis prevention rather than cardiovascular risk reduction

Rationale

Multiple large randomized trials of fibrates added to statin therapy in patients with elevated triglycerides failed to demonstrate reductions in major cardiovascular events. The failure of pemafibrate — a highly selective peroxisome proliferator-activated receptor-alpha modulator — despite achieving robust triglyceride lowering, effectively confirmed that triglyceride lowering per se is not sufficient to reduce cardiovascular events in patients already on statin therapy. This evidence has narrowed the clinical role of fibrates to severe hypertriglyceridemia above 500 milligrams per deciliter, where the acute risk of pancreatitis — not cardiovascular events — is the primary concern and where fenofibrate is first-line treatment. Triglyceride-rich remnant particles are associated with cardiovascular risk, but pharmacologically lowering triglycerides with fibrates has not translated this association into clinical benefit in the statin era.

Correct Answer

A — Niacin stimulates prostaglandin D2 release from cutaneous cells, causing cutaneous vasodilation; aspirin inhibits cyclooxygenase and blocks prostaglandin D2 synthesis, reducing the vasodilatory stimulus

Rationale

Niacin-induced flushing is a prostaglandin D2-mediated cutaneous vasodilatory reaction. Niacin stimulates prostaglandin D2 production in cutaneous cells, and prostaglandin D2 acts on dermal blood vessels to produce the characteristic vasodilation, redness, warmth, and itching. Because aspirin inhibits cyclooxygenase — the enzyme required for prostaglandin synthesis — aspirin pretreatment taken 30 minutes before the niacin dose reduces prostaglandin D2 production and substantially attenuates the flushing response. Extended-release niacin formulations also reduce flushing by producing a slower rise in plasma niacin concentrations. The reaction does not involve histamine receptors, nitric oxide pathways, or prostaglandin E2 as the primary mediator. Option D contains a partially accurate premise — niacin does activate the GPR109A receptor — but the mediator of flushing is prostaglandin D2, not prostaglandin E2, and the relevant aspirin mechanism is cyclooxygenase inhibition affecting prostaglandin D2 synthesis broadly.

Correct Answer

C — Bile acid sequestrants are large polymeric resins that non-specifically bind co-ingested medications in the intestinal lumen, physically preventing their absorption

Rationale

Bile acid sequestrants are large, non-absorbed polymeric resins that work by binding bile acids in the intestinal lumen. This same binding capacity extends non-specifically to many co-administered drugs, including warfarin, thyroid hormone, digoxin, statins, fibrates, thiazide diuretics, beta-blockers, and fat-soluble vitamins. By binding these agents in the intestinal lumen before they can be absorbed, bile acid sequestrants substantially reduce their bioavailability. The solution is temporal separation — taking all other oral medications at least one hour before or four to six hours after the bile acid sequestrant dose ensures that the other drugs are either already absorbed or not yet present in the lumen when the sequestrant is active. This interaction is entirely a physical lumenal binding mechanism; bile acid sequestrants do not alter gastric pH, do not induce cytochrome P450 enzymes, and do not meaningfully alter intestinal motility.

Correct Answer

B — Docosahexaenoic acid raises low-density lipoprotein cholesterol by approximately seven to nine percent, partially offsetting any cardiovascular benefit from triglyceride reduction, and may attenuate the anti-inflammatory and membrane-stabilizing effects of icosapentaenoic acid

Rationale

The divergence in cardiovascular outcomes between icosapentaenoic acid ethyl ester and docosahexaenoic acid-containing formulations has been attributed to several pharmacological differences. Docosahexaenoic acid raises low-density lipoprotein cholesterol by approximately seven to nine percent, which may partially counteract the cardiovascular benefit from triglyceride lowering. Docosahexaenoic acid may also attenuate some of icosapentaenoic acid's anti-inflammatory effects on vascular endothelium and plaque biology, as well as its effects on membrane composition and platelet function — mechanisms that extend beyond triglyceride lowering alone. Option C is partially true in that dose matters, but the content of the formulation — specifically the presence or absence of docosahexaenoic acid — is the key pharmacological distinction taught in this module. Docosahexaenoic acid does not activate peroxisome proliferator-activated receptor-alpha in a pharmacologically meaningful way comparable to fibrates.

Correct Answer

D — Niacin at pharmacological doses impairs insulin sensitivity, worsening glucose control by reducing insulin-mediated glucose uptake in peripheral tissues

Rationale

At the pharmacological doses used for lipid modification — 1.5 to 3 grams per day — niacin impairs insulin sensitivity in peripheral tissues including skeletal muscle and adipose tissue. This reduction in insulin sensitivity raises fasting glucose and impairs glucose tolerance, precipitating new-onset type 2 diabetes in susceptible individuals or worsening control in patients with existing diabetes. The diabetogenic effect is dose-dependent and is one of the significant adverse effects that contributed to niacin's abandonment for cardiovascular risk reduction. Niacin does not directly destroy pancreatic beta cells, does not block renal glucose transporters, and does not suppress insulin secretion via the GPR109A receptor as the primary mechanism of its diabetogenic effect — the GPR109A receptor on adipocytes mediates the lipid effects and flushing, not the glucose effects.

Correct Answer

A — Depletion of hepatic cholesterol by interrupted enterohepatic recirculation triggers compensatory upregulation of hepatic very low-density lipoprotein synthesis, raising plasma triglycerides as a secondary consequence

Rationale

Bile acid sequestrants interrupt enterohepatic bile acid recirculation, forcing the liver to convert more cholesterol into bile acids. The resulting depletion of hepatic cholesterol activates the sterol regulatory element-binding protein 2 pathway, which upregulates low-density lipoprotein receptor expression — the intended therapeutic effect. However, the same hepatic response to cholesterol depletion also upregulates very low-density lipoprotein synthesis as a compensatory mechanism, increasing the production and secretion of triglyceride-rich particles into the plasma. This typically raises triglycerides by five to ten percent and is a clinically meaningful concern in patients who already have elevated triglycerides. In patients with triglycerides above 300 milligrams per deciliter, this further elevation can approach the level where pancreatitis risk becomes significant, which is why bile acid sequestrants are avoided in this population. Bile acid sequestrants do not bind lipoprotein lipase, do not redirect dietary fat, and do not interact with peroxisome proliferator-activated receptor-alpha.

Correct Answer

C — Patients with triglycerides 135 to 499 milligrams per deciliter and established atherosclerotic cardiovascular disease or diabetes with additional risk factors already on statin therapy; the most notable adverse effect is a modestly increased risk of atrial fibrillation

Rationale

The REDUCE-IT trial enrolled patients with triglycerides of 135 to 499 milligrams per deciliter who had established atherosclerotic cardiovascular disease or diabetes with additional cardiovascular risk factors, all on background statin therapy. In this specific population, icosapentaenoic acid ethyl ester 4 grams per day reduced major cardiovascular events by 25 percent, establishing this as an American College of Cardiology and American Heart Association Class IIa recommendation for this indication. The most notable adverse effect is a modestly increased risk of atrial fibrillation, which should be discussed with patients who have pre-existing atrial fibrillation risk factors; the net cardiovascular benefit substantially outweighs this risk at the population level. Icosapentaenoic acid ethyl ester is not indicated for very high triglycerides above 500 milligrams per deciliter as the primary indication — that is the domain of fibrates for pancreatitis prevention. It does not cause rhabdomyolysis, new-onset diabetes, or hepatotoxicity at therapeutic doses.

Correct Answer

D — Fenofibrate, to reduce triglycerides and prevent acute pancreatitis — the primary goal at this triglyceride level — rather than to reduce cardiovascular events, which fibrates have not demonstrated on statin background

Rationale

At triglyceride levels above 500 milligrams per deciliter, the immediate clinical priority shifts from cardiovascular risk reduction to pancreatitis prevention. Accumulation of triglyceride-rich chylomicron remnants in the pancreatic microcirculation at these levels creates a risk of acute pancreatitis that requires specific pharmacological intervention. Fenofibrate is first-line for this indication. The choice of fenofibrate rather than gemfibrozil is important because gemfibrozil raises statin plasma concentrations by inhibiting hepatic uptake transporters and statin glucuronidation, substantially increasing the risk of rhabdomyolysis when combined with any statin. Fenofibrate carries substantially lower pharmacokinetic interaction risk with statins. Icosapentaenoic acid ethyl ester is indicated for triglycerides of 135 to 499 milligrams per deciliter for cardiovascular event reduction — not for severe hypertriglyceridemia above 500 milligrams per deciliter for pancreatitis prevention. Ezetimibe lowers low-density lipoprotein cholesterol but has minimal effect on triglycerides at this severity.

Correct Answer

B — Colesevelam is a polymeric resin that non-specifically binds warfarin in the intestinal lumen, reducing its absorption; taking warfarin one hour before ensures it is absorbed before the sequestrant is present in the lumen

Rationale

Bile acid sequestrants — including colesevelam — are large polymeric resins that bind bile acids in the intestinal lumen. This same binding capacity extends non-specifically to many co-administered drugs. Warfarin is one of the agents listed in the module as susceptible to this interaction; when taken at the same time as a bile acid sequestrant, warfarin molecules bind to the resin and are carried out in the stool rather than absorbed. The result is reduced warfarin bioavailability and potentially inadequate anticoagulation. Taking warfarin at least one hour before the sequestrant dose ensures that warfarin is absorbed from the upper intestine before colesevelam reaches the lumen in meaningful concentrations. Colesevelam is not systemically absorbed, does not induce cytochrome P450 enzymes, does not alter gastric pH, and does not deplete vitamin K from the lumen — its only mechanism of drug interaction is physical lumenal binding.

Correct Answer

A — Prescription icosapentaenoic acid ethyl ester 4 grams per day, because it is the only omega-3 formulation with proven cardiovascular event reduction in patients with this triglyceride level, cardiovascular disease, and diabetes on statin therapy

Rationale

This patient fits the REDUCE-IT trial population exactly: triglycerides of 135 to 499 milligrams per deciliter, established atherosclerotic cardiovascular disease, type 2 diabetes, and background statin therapy. In this population, prescription icosapentaenoic acid ethyl ester 4 grams per day demonstrated a 25 percent reduction in major cardiovascular events. Over-the-counter fish oil products containing docosahexaenoic acid have not demonstrated cardiovascular event reduction in adequately powered trials and are not an equivalent substitute — a large trial of high-dose icosapentaenoic acid plus docosahexaenoic acid found no cardiovascular benefit despite meaningful triglyceride lowering. Docosahexaenoic acid raises low-density lipoprotein cholesterol modestly and may attenuate some of icosapentaenoic acid's cardiovascular effects. The cardiovascular outcomes evidence is specific to the pure icosapentaenoic acid ethyl ester formulation at 4 grams per day — not to omega-3 dose in general.

Correct Answer

C — Colesevelam, which lowers low-density lipoprotein cholesterol and also has an additional approved indication for modest glycated hemoglobin reduction — approximately 0.5 percent — in type 2 diabetes

Rationale

Colesevelam is the bile acid sequestrant with a unique additional approved indication for modest glycated hemoglobin reduction of approximately 0.5 percent in patients with type 2 diabetes. This makes it particularly attractive in a statin-intolerant patient who needs low-density lipoprotein cholesterol lowering and also has type 2 diabetes, as a single agent can address both. Colesevelam is not systemically absorbed and therefore carries no systemic adverse effects, making it appropriate for patients who cannot tolerate systemic lipid-lowering agents. Cholestyramine and colestipol share the same primary lipid-lowering mechanism as colesevelam but do not have the additional diabetes indication, and their granular powder formulations are less well tolerated than colesevelam tablets. Fenofibrate primarily lowers triglycerides and does not lower low-density lipoprotein cholesterol reliably; it is not the agent of choice for low-density lipoprotein cholesterol reduction in a statin-intolerant patient.